Trials / Conditions / ALK-positive Advanced NSCLC
ALK-positive Advanced NSCLC
4 registered clinical trials studyying ALK-positive Advanced NSCLC — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operabl NCT06785584 | Fujian Medical University Union Hospital | Phase 4 |
| Completed | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell NCT03535740 | Ariad Pharmaceuticals | Phase 2 |
| Completed | Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small NCT03410108 | Takeda | Phase 2 |
| Terminated | Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients NCT02511184 | Pfizer | Phase 1 |